目的：观察糖皮质激素联合抗病毒药物综合治疗病毒性角膜内皮炎的临床效果和角膜内皮形态学的变化，并探讨治疗方案的安全性。

方法：回顾性分析2014-01/2015-12就诊于西安市第四医院的48例48眼病毒性角膜内皮炎患者的发病诱因、病史和临床表现，采用自身对照研究，比较糖皮质激素联合抗病毒药物综合治疗后3mo患者的治愈率、复发情况和角膜内皮形态学的变化。

结果：病毒性角膜内皮炎发病诱因较多，患者均有眼红、眼疼、畏光、流泪和视力下降、视物模糊等症状，临床表现包括视力下降、结膜睫状充血或混合充血、角膜水肿，可有角膜上皮小水泡、后弹力层皱褶、灰白色或羊脂状KP、眼压升高、虹膜后粘连，反复发作者发生角膜大泡。治疗1mo有效率达100%，治愈率达88%，且未见复发病例； 治疗2mo有效率和治愈率达100%，共1眼(2%)复发； 治疗3mo共2眼(4%)复发。治疗3mo后治疗组的细胞计数(t=2.952，P=0.004)和OCT角膜厚度(t=2.584，P=0.011)均低于对照组，差异有统计学意义； 治疗组的细胞多形性变异率(45.85%±6.29%)高于对照组(40.62%±5.16%)，差异有统计学意义(t=4.458，P<0.001)。治疗前治疗组的视力差于对照组，差异有统计学意义(Z=-5.766，P<0.001)； 治疗后治疗组的视力恢复到0.20(0.10～0.40)LogMAR，治疗前后差异有统计学意义(Z=-6.089，P<0.001)。

结论：病毒性角膜内皮炎的临床表现和病因复杂多样，应用抗病毒药物和糖皮质激素联合治疗，能够取得良好疗效，但是治疗后角膜内皮计数和角膜厚度减少，为治疗的安全性提出了更高的要求。

METHODS: The clinical data like predisposing factors, history and clinical manifestation were retrospectively analyzed, the 48 patients(48 eyes)with viral corneal dermatitis from January 2014 to December 2015 in Xi'an No.4 Hospital were included. A comparative study was conducted between affected eyes and healthy eyes. The cure rate, recurrence rate and corneal endothelial morphological changes of patients treated with combined treatment of glucocorticoid and antiviral drugs after 3mo were compared and analyzed statistically.

RESULTS: Corneal endotheliitis patients had many predisposing factors and symptoms like red eye, eye pain, photophobia, tears and decreased visual acuity, blurred vision and others, clinical manifestations include decreased visual acuity, conjunctival congestion or mixed ciliary congestion, corneal edema, corneal epithelium might have small blisters, Descemet membrane folds, gray white or white like KP, intraocular pressure increased, posterior synechia, cases of several recurrent had corneal bullous occurred. After 1mo of treatment, the effective rate was 100%, the cure rate was 88%, and there was no recurrence; after 2mo of treatment the effective rate and the cure rate was 100%, a total of 1 cases(2%)recurrence; treatment for 3mo, a total of 2 cases(4%)recurrence. After 3mo of treatment cell count(t=2.952, P=0.004)and corneal thickness by OCT(t=2.584, P=0.011)of the treatment group were lower than those of the control group, the difference was statistically significant; cell pleomorphic mutation rate(45.85%±6.29%)of the treatment group was higher than that of the control group(40.62%±5.16%), the difference was statistically significant(t=4.458, P<0.001). The visual acuity of treatment group was poorer before treatment than that of the control group, the difference was statistically significant(Z=-5.766, P<0.001); after treatment, the visual acuity increased to 0.20(0.10-0.40), there were significant differences before and after the treatment(Z=-6.089, P<0.001).

CONCLUSION: The clinical manifestations and etiology of viral corneal endotheliitis is complex. Application of antiviral drugs and glucocorticoid treatment, can obtain good effect, but after the treatment, corneal thickness and corneal endothelial cell count decreased, higher requirements for the safety of the treatment is needed.